Thompson Tamar's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Jul 17, 2026
- Accession no.
- 0001161697-26-000183
- Filed
- Jul 17, 2026, 4:15 PM ET
- Trade date
- Jul 15, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 7 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Thompson TamarCIK 0001839248 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | Common Stock, par value $0.001 per share | DReturned to the companyDisposed | −3,773 | $31.50 | −$118,849.5 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | Common Stock | DReturned to the companyDisposed | −40,000 | $0.00 | $0 | 0 | Direct | |
| Jul 15, 2026 | Common Stock | DReturned to the companyDisposed | −29,524 | $0.00 | $0 | 0 | Direct | |
| Jul 15, 2026 | Common Stock | DReturned to the companyDisposed | −23,248 | $0.00 | $0 | 0 | Direct | |
| Jul 15, 2026 | Common Stock | DReturned to the companyDisposed | −18,115 | $0.00 | $0 | 0 | Direct | |
| Jul 15, 2026 | Common Stock | DReturned to the companyDisposed | −1,414 | $0.00 | $0 | 0 | Direct | |
| Jul 15, 2026 | Common Stock | DReturned to the companyDisposed | −1,894 | $0.00 | $0 | 0 | Direct | |
| Jul 15, 2026 | Common Stock | DReturned to the companyDisposed | −5,468 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.